Johnson Johnson Walking Away Could Boost Long-Term Value
Johnson Johnson walking away from a GLP-1 obesity obsession signals a shift to a diversified, potentially more resili...
Pharma Stocks
Pharma Stocks collects four articles on big pharma movers, from Novo Nordisk to Merck, highlighting value, growth angles, and dividend potential to help smarter investing.
42 articlesAbbVie Stock Hits 52-Week High: Is It Priced Right
AbbVie stock recently surged to a fresh 52-week high, impressing bulls while raising questions about value. This guid...
Better Obesity Drug Race: Novo Nordisk vs Lilly 2026
In the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
Biotech Takeover Targets Wall Street Eyes After Apogee Deal
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Underrated Weight Loss Stocks: Two Buys for Long-Term Hold
The weight loss therapy wave has fireworks at the giants, but smart investors look for underrated weight loss stocks ...
Teva's Biosimilar Boom Just Beginnings: Is It Time to Buy?
Teva is turning the corner with a growing biosimilars roster and improving margins. This article examines whether tev...
Pfizer's Weight-Loss Data Just Upends Investor Bets
Pfizer is stepping into a high-stakes arena long led by Lilly and Novo Nordisk. This article analyzes what pfizer's w...
Prediction: Lilly Will Reach $1,200 in 2026 — Investment Thesis
Eli Lilly’s GLP-1 drugs are redefining growth in obesity and diabetes treatment. This article lays out why the stock ...
Reasons Lilly Remains a Buy: 3 Strong Drivers for Investors
Investors are eyeing Lilly for its resilient growth, strong pipeline, and shareholder-friendly strategy. This piece b...
Forget Zepbound: Lilly's Next Stock Signal for Investors
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
Bristol Myers Pfizer: Which High Yield Stock Wins Now?
Two pharma giants compete for your portfolio's income. This guide weighs yields, safety, and long-term risks to answe...
Johnson Johnson Hopes Dethrone AbbVie’s Growth Driver
Two pharma giants are wighting for a leadership position in immunology. This piece explains why Johnson Johnson hopes...